Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 14.8 %

Shares of EVOK stock opened at $4.26 on Tuesday. The stock has a market cap of $3.49 million, a PE ratio of -0.41 and a beta of 0.36. The business has a 50-day simple moving average of $5.08 and a 200-day simple moving average of $5.52. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $17.88.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). The company had revenue of $2.55 million during the quarter. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.